HR Execs on the Move

CipherHealth

www.cipherhealth.com

 
CipherHealth is an award-winning and proven technology solutions partner committed to enhancing communication and care throughout the patient journey. Since 2009, CipherHealth has helped shape the patient engagement category, delivering groundbreaking products to help care providers effectively and efficiently deliver quality care for their patients. CipherHealth`s suite of patient engagement programs sets new standards for care and empowers healthcare organizations to create purposeful conversations to ensure the best possible outcomes for staff members, patients, and their loved ones.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Summer Brown
Chief Customer Officer Profile
Shawn Lemerise
Chief Customer Officer Profile
Todd Jaschke
Vice President, Customer Success Operations Profile
Noa Walsky
Vice President, Product Marketing Profile
Mandana Varahrami
Chief Product Officer Profile

Similar Companies

Kootenai Prosthetics and Orthotics

Kootenai Prosthetics & Orthotics is a Coeur D Alene, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galveston County Health District

The Galveston County Health District includes both childhood and adult immunizations in its strategic health plan which is a tool guiding their activities through 2010.

Prairie Senior Cottages

Prairie Senior Cottages is a Willmar, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.

University of Pittsburgh Center for BioSecurity

University of Pittsburgh Center for BioSecurity is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.